Kuros Biosciences AG
SIX:KURN

Watchlist Manager
Kuros Biosciences AG Logo
Kuros Biosciences AG
SIX:KURN
Watchlist
Price: 27.8 CHF -2.11% Market Closed
Market Cap: 1B CHF
Have any thoughts about
Kuros Biosciences AG?
Write Note

P/FCFE
Price to FCFE

-256.2
Current
-10.3
Median
27.3
Industry
Lower than median
Lower than industry value

Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

P/FCFE
-256.2
=
Market Cap
1B CHF
/
FCFE
-4m CHF
All Countries
Close
Market Cap P/FCFE
CH
Kuros Biosciences AG
SIX:KURN
1B CHF -256.2
FR
Pharnext SCA
OTC:PNEXF
6T USD -3 136 942.1
US
Abbvie Inc
NYSE:ABBV
352.5B USD 14.1
US
Amgen Inc
NASDAQ:AMGN
174.8B USD 29.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
133.2B USD -95.2
US
Gilead Sciences Inc
NASDAQ:GILD
120.3B USD 12
US
Epizyme Inc
F:EPE
94.1B EUR -437.4
AU
CSL Ltd
ASX:CSL
137.9B AUD 82.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
91.2B USD 27.5
US
Seagen Inc
F:SGT
39.3B EUR -60.1
NL
argenx SE
XBRU:ARGX
33.2B EUR -107.5
 
CH
Kuros Biosciences AG
SIX:KURN
Average P/FCFE: 33.1
Negative Multiple: -256.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -3 136 942.1
US
Abbvie Inc
NYSE:ABBV
14.1
US
Amgen Inc
NASDAQ:AMGN
29.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -95.2
US
Gilead Sciences Inc
NASDAQ:GILD
12
US
E
Epizyme Inc
F:EPE
Negative Multiple: -437.4
AU
CSL Ltd
ASX:CSL
82.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
27.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1
NL
argenx SE
XBRU:ARGX
Negative Multiple: -107.5

P/FCFE Forward Multiples

Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/FCFE
N/A
2-Years Forward
P/FCFE
N/A
3-Years Forward
P/FCFE
N/A

See Also

Discover More